Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786474 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,884
- Enrollment target
NCT00786474: Completed Phase 3 study, sponsored by Duke University.
NCT00786474 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 1,884 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (144% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00786474, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,884 participants
- Enrollment target
Study Summary
Blood thinners, such as warfarin, prevent blood clots from forming, thereby reducing the risk of a stroke or heart attack. When people undergo surgery or certain procedures, they must stop using warfarin to prevent too much bleeding during and after the surgery or procedure. Some doctors prescribe a different blood thinner, one that works more quickly and wears off more quickly, to bridge the gap between starting and stopping warfarin. However, this short-term treatment is expensive, may increase the risk of bleeding, and has not been proven effective. This study will determine whether a bridging blood thinner called dalteparin is helpful or harmful for people with atrial fibrillation who stop taking warfarin in preparation for surgery or a procedure.
Primary Outcome
The events are defined as arterial thromboembolism: stokes, transient ischemic attack and systemic embolism events were independently and blindly adjudicated
Interventions
- DRUG Placebo
- DRUG Dalteparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,884 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
What the finished NCT00786474 record still lists
NCT00786474 is an interventional study that assigns participants to a tested intervention. Its 1,884 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (144% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00786474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00786474 about?
NCT00786474 is a clinical study titled "Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)". Blood thinners, such as warfarin, prevent blood clots from forming, thereby reducing the risk of a stroke or heart attack. When people undergo surgery or certain procedures, they must stop using warfarin to prevent too much bleeding during and after the surgery or procedure. Some doctors prescribe a...
What is the current status of trial NCT00786474?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,884 participants. The study started on 2009-07. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00786474?
The interventions under investigation include: Placebo (DRUG), Dalteparin (DRUG).
Who is sponsoring clinical trial NCT00786474?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00786474's enrollment target sits among peer trials
1,884 113th of 2000 higher than 1,888 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06438640 · 1,881 participants · NA
Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT06891898 · 1,875 participants
The iLet Experience Study
- NCT07356089 · 1,875 participants
Twiist Postmarket Surveillance Study for Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia